The pressure injectable M/29 Midterm catheter series is the latest addition to Flexicath’s M/29 family of midline catheters.
The company describes the M/29 Midterm as “the world’s first IV catheter solution to provide a ‘built in’ 360-degree Maximum Barrier against airborne and touch-borne contamination during the insertion process and offers a simple to place intermediate dwell alternative for patients needing IV therapy for less than 30 days,” in the release.
Flexicath is headquartered in Pittsburgh.
Related Articles on FDA Clearances:
Hollywog Receives FDA Clearances for Remote Controlled Back Pain Devices
Toshiba Receives FDA Clearance for Vantage Titan 1.5T MRI
Covalon Receives FDA Clearance for Antimicrobial Silicone Wound Dressing
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
